<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706065</url>
  </required_header>
  <id_info>
    <org_study_id>aswan</org_study_id>
    <nct_id>NCT04706065</nct_id>
  </id_info>
  <brief_title>SHMT1 Polymorphism in Parkinson's Disease,</brief_title>
  <official_title>Genetic Polymorphisms of Serine Hydroxylmethyl Transferase 1 (SHMT1) in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson Disease (PD) is the most common movement disorder and represents the second most&#xD;
      common degenerative disease of the central nervous system . SHMT has been shown to be&#xD;
      associated with various diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This case -control observational prospective study will conducted on 40 patients with PD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>polymorphism of SHMT1gene</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the role of SHMT1plymorphism in pathogenesis PD</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the relationship of Shmt1 polymorphism to the severity of Parkinson disease</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Study the Role of SHMT1 Polymorphism in Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>GROUP 1</arm_group_label>
    <description>Group 1 (patients with PD) All participants will be subjected to thorough history taking, full clinical and neurological examination. Diagnosis of PD by using Brain Bank Criteria for diagnosis of Parkinson Disease , assessment of the severity of PD by using PDRS and evaluation of cognitive functions using MMSE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Group 2 (controls) All participants will be subjected to thorough history taking, full clinical and neurological examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SHMT1 polymorphism</intervention_name>
    <description>It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.</description>
    <arm_group_label>GROUP 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with parkinson diisease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age â‰¥ 50 years.&#xD;
&#xD;
          -  Patients with PD diagnosed according to the United Kingdom Parkinson's Disease Society&#xD;
             Brain Bank (UK PDS Brain Bank diagnostic criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with parkinsonian plus syndrome&#xD;
&#xD;
               -  Patients with secondary parkinsonism&#xD;
&#xD;
               -  Patients with other chronic comorbidities (renal, hepatic, and endocrinal&#xD;
                  disturbances and chronic chest disease.)&#xD;
&#xD;
               -  Past and /or present history of epilepsy.&#xD;
&#xD;
               -  Patients with disturbed conscious level.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abeer a tony, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Effat a Tony, MD</last_name>
    <phone>+201097330309</phone>
    <email>effattony@aun.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>abeer a tony, MD</last_name>
    <phone>+201005389084</phone>
    <email>abeer.tony@aswu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Effat abdelhady tony</name>
      <address>
        <city>Assuit</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Effat a tony, MD</last_name>
      <phone>01097330309</phone>
      <email>effattony@aun.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>abeer a tony, MD</last_name>
      <phone>+201005389084</phone>
      <email>abeer_tony70@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 3, 2021</study_first_submitted>
  <study_first_submitted_qc>January 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Effat AETony, MD</investigator_full_name>
    <investigator_title>professor of internal medicine</investigator_title>
  </responsible_party>
  <keyword>SHMT1 polymorphism</keyword>
  <keyword>Parkinson disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

